Trial results

$VSTM — VS-7375

Verastem, Inc. (VSTM) VS-7375: trial results in mCRC and mPDAC, 2026.

Research by Catalyst Intel

The catalyst

"Plan to report mature data from the TARGET-D 101 mCRC 900 mg combination with anti-EGFR cohort and initial data from the 600 mg VS-7375 plus cetuximab combination cohort in mPDAC by year-end 2026."

— Verastem Oncology, 8-K filed 2026-10-14 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

VSTM-VS7375-2026

Company

Verastem, Inc.

Kind

Trial results

Indication

mCRC and mPDAC

Window

2026-01-01 – 2026-12-31

Status

slate

The bar

No bar has been published for this event yet.

Verdicts

Sealed with the bar. Any verdict for this event reaches this page on 2027-01-30; subscribers get it on the day.